Phase I - II safety study of filgrastim (neupogen) to improve left ventricular function after severe acute myocardial infarction

Trial Profile

Phase I - II safety study of filgrastim (neupogen) to improve left ventricular function after severe acute myocardial infarction

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2008

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 18 Sep 2008 Primary outcome identified as death or myocardial rupture at 30 days and change in left ventricular ejection fraction from baseline to 30 days as reported by ClinicalTrials.gov.
    • 18 Sep 2008 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
    • 18 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top